Cargando…
A Phase 1, Randomized, Open‐Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects
OBJECTIVE: To investigate and compare the safety and the pharmacokinetics of dihydroergotamine (DHE) after administration of intranasal DHE powder (STS101), intranasal DHE spray (Migranal(®)), and intramuscular (IM) DHE injection in healthy subjects. METHODS: This was a 2‐part, active‐controlled, 3‐...
Autores principales: | Albrecht, Detlef, Iwashima, Mic, Dillon, Debbie, Harris, Stuart, Levy, Jeff |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154716/ https://www.ncbi.nlm.nih.gov/pubmed/31985049 http://dx.doi.org/10.1111/head.13737 |
Ejemplares similares
-
Dihydroergotamine (DHE) – Then and Now: A Narrative Review
por: Silberstein, Stephen D., et al.
Publicado: (2019) -
Delivery of Dihydroergotamine Mesylate to the Upper Nasal Space for the Acute Treatment of Migraine: Technology in Action
por: Cooper, Wade, et al.
Publicado: (2022) -
Updated Evaluation of IV Dihydroergotamine (DHE) for Refractory Migraine: Patient Selection and Special Considerations
por: Shafqat, Rafia, et al.
Publicado: (2020) -
STOP 301: A Phase 3, open‐label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD(®)) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients
por: Smith, Timothy R., et al.
Publicado: (2021) -
Aprepitant for the management of nausea with inpatient IV dihydroergotamine
por: Chou, Denise E., et al.
Publicado: (2016)